颗粒或非颗粒类固醇是否决定了周关节注射有效控制术后TKR疼痛的决定因素? 网络元分析 网络元分析
Mohammad Zaim Chilmi1,2, Julius Albert Sugianto1, Zainurrahman Kurnia Putra1
1Department of Orthopedic and Traumatology, Faculty of Medicine, Universitas Airlangga / Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Journal of orthopaedics
|August 9, 2023
概括
颗粒性或非颗粒性类固醇对全膝关节置换 (TKR) 疼痛表现出类似的有效性. 特定的类固醇类型,而不是其颗粒性质,是TKR后术后疼痛管理的关键.
科学领域:
- 整形外科 整形外科 整形外科
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
背景情况:
- 带有类固醇的周关节注射 (PAI) 用于在全膝关节置换 (TKR) 后进行术后疼痛控制.
- 有证据表明,PAI可以改善疼痛管理,但最佳类固醇类型尚不清楚.
- 颗粒和非颗粒类固醇具有不同的特性,可能会影响其有效性.
研究的目的:
- 为了比较颗粒物与非颗粒物类固醇周关节注射在TKR患者的术后疼痛控制的疗效.
- 为了确定类固醇颗粒大小是否会影响TKR后的疼痛减轻.
- 通过网络元分析来综合现有证据.
主要方法:
- 根据PRISMA指南进行了网络元分析.
- 分析了对TKR的PAI中颗粒物 (Triamcinolone,甲基prednisolone,prednisolone) 与非颗粒物 (dexamethasone,betamethasone) 类固醇进行比较的研究.
- 从对108篇论文的初步搜索中,包括了10项研究.
主要成果:
- 在术后第一天 (POD1) 中,在颗粒体和非颗粒体类固醇之间没有观察到视觉模拟量表 (VAS) 减少的显著差异.
- 非颗粒类固醇在术后第3天 (POD3) 显示出更大VAS减少的趋势.
- 亚组分析表明,特定的类固醇类型,而不是其颗粒性质,影响了VAS减少,POD1和POD3之间的结果不一致.
结论:
- 无论是颗粒物还是非颗粒物类固醇都不会显著影响TKR后整体疼痛管理.
- 在周关节注射中使用的特定类型的类固醇是术后VAS减少的更关键因素,而不是其颗粒状况.
- 可能需要进一步的研究来阐明不同类固醇配方在TKR缓解疼痛中的确切作用.
相关概念视频
Analgesia and Pain Management
657
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
657
Local Anesthetics: Pharmacokinetics
799
The potency and duration of action of local anesthetics (LAs) are determined by their pharmacokinetics. Pharmacokinetics describes how LAs are absorbed, distributed, metabolized, and eliminated from the body. When administered to the vascular tissues, LAs are quickly absorbed and enter the systemic circulation, reducing their localized effects. Adding vasoconstrictors such as epinephrine to LAs reduces their absorption into the systemic circulation, making them clinically effective. The...
799
Parenteral Anesthetics: Overview
155
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
155
Local Anesthetics: Clinical Application as Epidural Anesthesia
458
Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
458
Opioid Analgesics: Synthetic and Semisynthetic Opioids
335
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
335


